Skip to main content
Premium Trial:

Request an Annual Quote

Pathogenica, Targeted Genomics Partner to Bring HAI Detection Kit to Australia, NZ

NEW YORK (GenomeWeb News) – Targeted Genomics announced today a partnership to distribute Pathogenica's HAI BioDetection kit in Australia and New Zealand.

The kit for hospital-acquired infections is based on DNA sequencing technology and enables the identification of infectious diseases "with sequence-specific resolution at a scale that makes hospital-wide screening practical," Canberra, Australia-based Targeted Genomics said. The kit allows for the rapid characterization and tracking of infectious agents, resulting in better healthcare for patients and a reduction in healthcare costs, it added.

The kit can detect 12 bacteria commonly associated with HAI and 18 resistance gene families in one assay. It can simultaneously screen up to 24 samples and provide sample-to-result turnaround in less than 12 hours.

The kit is for research-use only, Targeted Genomics noted.

As part of their agreement, Targeted Genomics and Boston-based Pathogenica also have agreed to develop the technology for additional uses in Australia.

Financial terms of the exclusive deal were not disclosed.

Pathogenica and Takara Bio inked an agreement late last year to bring the HAI BioDetection Kit to Japan. About a year ago, Pathogenica and Life Technologies reached a deal to make the kit available in Japan on the Ion Torrent platform.